1. Home
  2. TTRX vs DMO Comparison

TTRX vs DMO Comparison

Compare TTRX & DMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$5.70

Market Cap

107.2M

Sector

Health Care

ML Signal

HOLD

Logo Western Asset Mortgage Opportunity Fund Inc.

DMO

Western Asset Mortgage Opportunity Fund Inc.

HOLD

Current Price

$10.82

Market Cap

127.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTRX
DMO
Founded
2015
N/A
Country
United States
United States
Employees
2
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
107.2M
127.4M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
TTRX
DMO
Price
$5.70
$10.82
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
52.4K
35.1K
Earning Date
05-31-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$10.42
52 Week High
$6.75
$12.11

Technical Indicators

Market Signals
Indicator
TTRX
DMO
Relative Strength Index (RSI) 68.94 33.32
Support Level $3.92 $10.71
Resistance Level N/A $11.20
Average True Range (ATR) 0.55 0.13
MACD 0.13 -0.04
Stochastic Oscillator 69.46 11.58

Price Performance

Historical Comparison
TTRX
DMO

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

About DMO Western Asset Mortgage Opportunity Fund Inc.

Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.

Share on Social Networks: